Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-25
2006-04-25
Hartley, Michael (Department: 1712)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S283000
Reexamination Certificate
active
07034024
ABSTRACT:
The invention concerns a product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent, in particular farnesyltransferase inhibitors, taxol or gemcitabin, for simultaneous, separate or prolonged therapeutic use in cancer treatment.
REFERENCES:
patent: 5565478 (1996-10-01), Kohn et al.
patent: 6333333 (2001-12-01), Bishop et al.
patent: 6342487 (2002-01-01), Riou et al.
patent: 6617331 (2003-09-01), Gray et al.
patent: 9730053 (1997-08-01), None
Gordon Thomas
Lonchampt Marie-Odile
Morgan Barry
Prevost Grégoire
Hartley Michael
Muserlian Charles A.
Societe de Conseils de Recherches et d'Applications Scientifique
LandOfFree
Product inhibiting transduction of G heterotrimeric protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Product inhibiting transduction of G heterotrimeric protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Product inhibiting transduction of G heterotrimeric protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3575592